Overview

Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation

Status:
Terminated

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the effect of dexlansoprazole once daily (QD) and twice daily (BID) dosing on the recurrence of intestinal metaplasia (IM) in participants who achieved complete eradication of Barrett's esophagus (BE) with high-grade dysplasia (HGD) following radiofrequency ablation (RFA).

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

Dexlansoprazole
Lansoprazole